195 related articles for article (PubMed ID: 38365417)
1. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
Brito M; Rufatto R; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Menezes A; Ataídes R; Batista Pereira D; Lacerda M
Lancet Glob Health; 2024 Mar; 12(3):e467-e477. PubMed ID: 38365417
[TBL] [Abstract][Full Text] [Related]
2. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
Brito M; Rufatto R; Brito-Sousa JD; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Batista Pereira D; Lacerda M
Lancet Infect Dis; 2024 Jun; 24(6):629-638. PubMed ID: 38452779
[TBL] [Abstract][Full Text] [Related]
3. Perspectives of healthcare professionals on training for quantitative G6PD testing during implementation of tafenoquine in Brazil (QualiTRuST Study).
Santos A; Brito M; Silva E; Rocha F; Oliveira A; Dávila R; Gama H; Albuquerque J; Paiva M; Baía-Silva D; Sampaio V; Balieiro P; Rufatto R; Grewal Daumerie P; Peterka C; Edilson Lima F; Monteiro W; Arcanjo A; Silva R; Batista Pereira D; Lacerda M; Murta F
PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012197. PubMed ID: 38837977
[TBL] [Abstract][Full Text] [Related]
4. Tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study.
Sutanto I; Soebandrio A; Ekawati LL; Chand K; Noviyanti R; Satyagraha AW; Subekti D; Santy YW; Crenna-Darusallam C; Instiaty I; Budiman W; Prasetya CB; Lardo S; Elyazar I; Duparc S; Cedar E; Rolfe K; Fernando D; Berni A; Jones S; Kleim JP; Fletcher K; Sharma H; Martin A; Taylor M; Goyal N; Green JA; Tan LK; Baird JK
Lancet Infect Dis; 2023 Oct; 23(10):1153-1163. PubMed ID: 37236221
[TBL] [Abstract][Full Text] [Related]
5. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
[TBL] [Abstract][Full Text] [Related]
6. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
Watson J; Taylor WRJ; Bancone G; Chu CS; Jittamala P; White NJ
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006440. PubMed ID: 29677199
[TBL] [Abstract][Full Text] [Related]
7. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
[TBL] [Abstract][Full Text] [Related]
8. Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
Sharma R; Sharma H; Jones S; Borghini-Fuhrer I; Domingo GJ; Gibson RA; Rolfe K; Tan L; Fiţa IG; Chen C; Bird P; Pingle A; Duparc S
Malar J; 2024 May; 23(1):145. PubMed ID: 38741094
[TBL] [Abstract][Full Text] [Related]
9. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rajapakse S; Rodrigo C; Fernando SD
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
[TBL] [Abstract][Full Text] [Related]
10. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
[TBL] [Abstract][Full Text] [Related]
11. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C; Rajapakse S; Fernando D
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD010458. PubMed ID: 32892362
[TBL] [Abstract][Full Text] [Related]
12. Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model.
Price DJ; Nekkab N; Monteiro WM; Villela DAM; Simpson JA; Lacerda MVG; White MT; Devine A
PLoS Med; 2024 Jan; 21(1):e1004255. PubMed ID: 38194420
[TBL] [Abstract][Full Text] [Related]
13. Radical cure for Plasmodium vivax malaria after G6PD qualitative testing in four provinces in Cambodia, results from Phase I implementation.
Lek D; Tsai YC; Hirano J; Sovannaroth S; Bunreth V; Vonn P; Vannthen O; Bunkea T; Samphornarann T; Sokomar N; Sarath M; Kheang ST; Wong E; Burbach MK; Hughes J; Rekol H
Malar J; 2024 Feb; 23(1):56. PubMed ID: 38395925
[TBL] [Abstract][Full Text] [Related]
14. G6PD testing and radical cure for Plasmodium vivax in Cambodia: A mixed methods implementation study.
Kheang ST; Ridley R; Ngeth E; Ir P; Ngor P; Sovannaroth S; Lek D; Phon S; Kak N; Yeung S
PLoS One; 2022; 17(10):e0275822. PubMed ID: 36264996
[TBL] [Abstract][Full Text] [Related]
15. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.
Chu CS; Bancone G; Moore KA; Win HH; Thitipanawan N; Po C; Chowwiwat N; Raksapraidee R; Wilairisak P; Phyo AP; Keereecharoen L; Proux S; Charunwatthana P; Nosten F; White NJ
PLoS Med; 2017 Feb; 14(2):e1002224. PubMed ID: 28170391
[TBL] [Abstract][Full Text] [Related]
16. Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study).
Brito-Sousa JD; Murta F; Vitor-Silva S; Sampaio VS; Mendes MO; Brito MAM; Batista TSB; Santos APC; Marques LLG; Barbosa LRA; Melo MM; Baia-da-Silva DC; Silva-Neto AV; Santos TC; Souza BKA; Figueiredo EFG; Silva EL; Rodovalho S; Nakagawa TH; Arcanjo AR; Siqueira AM; Melo GC; Recht J; Domingo GJ; Bassat Q; Bancone G; Monteiro WM; Lacerda MVG
PLoS Negl Trop Dis; 2021 May; 15(5):e0009415. PubMed ID: 34003840
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Sex-Stratified
Devine A; Howes RE; Price DJ; Moore KA; Ley B; Simpson JA; Dittrich S; Price RN
Am J Trop Med Hyg; 2020 Jul; 103(1):394-403. PubMed ID: 32372747
[TBL] [Abstract][Full Text] [Related]
18. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
19. Estimated impact of tafenoquine for Plasmodium vivax control and elimination in Brazil: A modelling study.
Nekkab N; Lana R; Lacerda M; Obadia T; Siqueira A; Monteiro W; Villela D; Mueller I; White M
PLoS Med; 2021 Apr; 18(4):e1003535. PubMed ID: 33891582
[TBL] [Abstract][Full Text] [Related]
20. Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
Thriemer K; Degaga TS; Christian M; Alam MS; Rajasekhar M; Ley B; Hossain MS; Kibria MG; Tego TT; Abate DT; Weston S; Mnjala H; Rumaseb A; Satyagraha AW; Sadhewa A; Panggalo LV; Ekawati LL; Lee G; Anose RT; Kiros FG; Simpson JA; Karahalios A; Woyessa A; Baird JK; Sutanto I; Hailu A; Price RN
Lancet; 2023 Dec; 402(10417):2101-2110. PubMed ID: 37979594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
